Immunosuppression in uveitis therapy.
Van Gelder
R N
RN
Department of Ophthalmology and Visual Sciences, Washington University Medical School, St. Louis, MO 63110, USA.
Kaplan
H J
HJ
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D019393:Arrestin / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007167:Immunotherapy; D008727:Methotrexate / Q000627:therapeutic use; D051381:Rats; D013256:Steroids / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy*
D019393:Arrestin; D007166:Immunosuppressive Agents; D013256:Steroids; D002699:Chlorambucil; D016572:Cyclosporine; D003520:Cyclophosphamide; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate